Sign inJoin waitlistJoin the waitlist

Robert DeBernardo

Associate Professor, Obstetrics & Gynecology, Cleveland Clinic · Case Western Reserve University

Credentials: · · · ·

History

Case Western Reserve University
Present

Gynecologic Oncology
Massachusetts General Hospital
2001–2004
Obstetrics and Gynecology
Johns Hopkins Hospital
1997–2001
Johns Hopkins University School of Medicine
1998–2001
Temple University School of Medicine
1993–1997

Research

Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1
Blood · 2007 · 162 citations
Interferon-α is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers
PLoS ONE · 2013 · 133 citations
IL-15 promotes activation and expansion of CD8+ T cells in HIV-1 infection
Journal of Clinical Investigation · 2016 · 105 citations

Peter Rose
30 papers
Chad Michener
26 papers
Roberto Vargas
15 papers · 1 as a fellow
Anthony Costales
11 papers · 11 as a fellow
CK
Charles Kunos
11 papers
Molly Morton
10 papers · 10 as a resident
AC
Anna Chichura
9 papers · 9 as a resident
Morgan Gruner
9 papers · 9 as a resident
Steven Waggoner
9 papers
Haider Mahdi
8 papers · 7 as a fellow
Max Horowitz
8 papers · 8 as a fellow
Danielle Chau
6 papers · 5 as a fellow

Clinical trials

Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
Principal investigator · Completed · Phase 2
Case Comprehensive Cancer Center
2009–2012
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Site PI · Recruiting · Phase 3
GOG Foundation
2024–2034
Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)
Sub-investigator · Recruiting · Phase 2
Frantz Viral Therapeutics, LLC
2023–2027
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
Sub-investigator · Recruiting · Phase 2
Frantz Viral Therapeutics, LLC
2020–2026